Abstract 54P
Background
Brain tumors are the most common tumors causing dysfunctions and the most fatal types of cancers. Patients with Parkinson’s disease (PD), the second most common neurodegenerative disorders, may be at high risk for brain tumors due to synucleins expression, chronic neuro-inflammation, levodopa therapy and radiations, but there is still controversy especially in Asia. Therefore, we conducted a nationwide population-based cohort study to assess the risk of brain tumors in patients with PD in South Korea.
Methods
We analyzed 52,009 patients diagnosed with PD between 2010 and 2015, and the age- and sex-matched 260,045 individuals without PD (mean age: 71.3 years; 40.8% men), using the data from the Korean National Health Insurance Database. Patients previously diagnosed with cancer were excluded. The cohorts were followed up to 2016 for cancer development. Cox proportional hazards regression models were used to evaluate the association between PD and brain cancer.
Results
Patients with PD had a higher brain cancer risk (hazard ratio [HR], 1.73; 95% confidence interval [CI], 1.05–2.85) in female patients with PD than in those without PD after adjustment for multiple covariates. There was no significant difference in brain tumor incidence between the two cohorts in men (HR, 1.02; 95% CI, 0.52-2.02).
Conclusions
This nationwide population-based cohort study revealed that patients with PD had higher risk of brain tumors than those without PD in Korea. Further studies are required to determine the underlying mechanisms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract